Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
29
11
2021
medline:
29
1
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
One in eight patients unfortunately suffers a new stroke within 5 years of their first stroke, even today. Research in precision medicine could lead to a more individualized treatment allocation, possibly achieving lower recurrence rates of ischemic stroke. In this narrative review, we aim to discuss potential clinical implementation of several promising candidate blood biomarkers. We discuss specifically some promising blood-based biomarkers, which may improve the identification of underlying causes as well as risk stratification of patients according to their specific cerebrovascular risk factor pattern. Multimodal profiling of ischemic stroke patients by means of blood biomarkers, in addition to established clinical and neuroradiological data, may allow in the future a refinement of decision algorithms for treatment allocation in secondary ischemic stroke prevention.
Identifiants
pubmed: 34839341
doi: 10.1097/WCO.0000000000001011
pii: 00019052-202202000-00009
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-54Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Esenwa C, Gutierrez J. Secondary stroke prevention: challenges and solutions. Vasc Health Risk Manag 2015; 11:437–450.
Flach C, Muruet W, Wolfe CDA, et al. Risk and secondary prevention of stroke recurrence: a population-base cohort study. Stroke 2020; 51:2435–2444.
Khanevski AN, Bjerkreim AT, Novotny V, et al. NOR-STROKE study group. Recurrent ischemic stroke: incidence, predictors, and impact on mortality. Acta Neurol Scand 2019; 140:3–8.
Zheng S, Yao B. Impact of risk factors for recurrence after the first ischemic stroke in adults: a systematic review and meta-analysis. J Clin Neurosci 2019; 60:24–30.
Boehme C, Toell T, Mayer L, et al. The dimension of preventable stroke in a large representative patient cohort. Neurology 2019; 93:e2121–e2132.
Adams HP, Woolson RF, Clarke WR, et al. Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Control Clin Trials 1997; 18:358–377.
Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001; 32:2735–2740.
Hart RG, Diener HC, Coutts SB, et al. Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13:429–438.
Radu RA, Terecoasă EO, Băjenaru OA, Tiu C. Etiologic classification of ischemic stroke: where do we stand? Clin Neurol Neurosurg 2017; 159:93–106.
Amarenco P, Bogousslavsky J, Caplan LR, et al. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis 2013; 36:1–5.
Patel AR, Desai S. The underlying stroke etiology: a comparison of two classifications in a rural setup. Cureus 2019; 11:e5157.
Amarenco P, Denison H, Evans SR, et al. THALES Steering Committee and Investigators∗. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. Stroke 2020; 51:3504–3513.
König IR, Fuchs O, Hansen G, et al. What is precision medicine? Eur Respir J 2017; 50:
Robinson PN. Deep phenotyping for precision medicine. Hum Mutat 2012; 33:777–780.
Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood) 2018; 37:694–701.
Simpkins AN, Janowski M, Oz HS, et al. Biomarker application for precision medicine in stroke. Transl Stroke Res 2020; 11:615–627.
Ramiro L, García-Berrocoso T, Briansó F, et al. Integrative multiomics analysis to characterize human brain ischemia. Mol Neurobiol 2021; 58:4107–4121.
Maida CD, Norrito RL, Daidone M, et al. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches. Int J Mol Sci 2020; 21:6454.
Low A, Mak E, Rowe JB, et al. Inflammation and cerebral small vessel disease: a systematic review. Ageing Res Rev 2019; 53:100916.
Kelly PJ, Murphy S, Coveney S, et al. Anti-inflammatory approaches to ischaemic stroke prevention. J Neurol Neurosurg Psychiatry 2018; 89:211–218.
Libby P. Inflammation in atherosclerosis-no longer a theory. Clin Chem 2021; 67:131–142.
Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35:1782–1791.
Dieden A, Malan L, Mels CMC, et al. Exploring biomarkers associated with deteriorating vascular health using a targeted proteomics chip: the SABPA study. Medicine (Baltimore) 2021; 100:e25936.
Kulasingam A, Hvas AM, Grove EL, et al. Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction. Thromb Res 2018; 172:21–28.
Andersen T, Ueland T, Ghukasyan Lakic T, et al. C-X-C ligand 16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2019; 39:2402–2410.
Ridker PM, MacFadyen JG, Everett BM, et al. CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018; 391:319–328.
Nidorf SM, Fiolet ATL, Mosterd A, et al. LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med 2020; 383:1838–1847.
Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J 2021; 42:2745–2760.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61:404–410.
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381:2497–2505.
Samuel M, Tardif JC, Khairy P, et al. Cost-effectiveness of low-dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes 2020; 7:486–495.
Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS Randomized Clinical Trial. Circulation 2020; 142:1890–1900.
Yilmaz E, Akay KH. The efficacy of colchicine on carotid intima-media thickness: a prospective comparative study. J Stroke Cerebrovasc Dis 2021; 30:105580.
Kelly P, Weimar C, Lemmens R, et al. Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial. Eur Stroke J 2021; 6:222–228.
Centre N CT. Colchicine After Stroke to Prevent Event Recurrence (CASPER). 2020 . Available at: https://ctc.usyd.edu.au/our-work/research-divisions/cardiovascular/start-up-and-active-trials/casper/ . [Accessed 27 September 2021]
Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke 2021; 52:2697–2706.
Flint AC, Conell C, Ren X, et al. Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. Stroke 2017; 48:1788–1794.
Ahmed N, Audebert H, Turc G, et al. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018. Eur Stroke J 2019; 4:307–317.
Kloska A, Malinowska M, Gabig-Cimińska M, Jakóbkiewicz-Banecka J. Lipids and lipid mediators associated with the risk and pathology of ischemic stroke. Int J Mol Sci 2020; 21:3618.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140:e596–e646.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111–188.
Arnold M, Schweizer J, Nakas CT, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J 2021; 42:2186–2196.
Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63:1278–1288.
Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014; 114:711–715.
Afanasieva O, Ezhov MV, Klesareva E, et al. Effect of evolocumab on lipoprotein(a) and PCSK9 in healthy individuals with elevated lipoprotein(a) level. J Cardiovasc Dev Dis 2020; 7:45.
Luquero A, Badimon L, Borrell-Pages M. PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation. Front Cardiovasc Med 2021; 8:639727.
Fogacci F, Ferri N, Toth PP, et al. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials. Drugs 2019; 79:751–766.
Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388:2239–2253.
Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med 2017; 377:296–297.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020; 382:244–255.
Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011; 48 (Pt 6):498–515.
German CA, Shapiro MD. Assessing atherosclerotic cardiovascular disease risk with advanced lipid testing: state of the science. Eur Cardiol 2020; 15:e56.
Ference BA, Kastelein JJP, Catapano AL. Lipids and Lipoproteins in 2020. JAMA 2020; 324:595–596.
Contois JH, Delatour V. Apolipoprotein B measurement: need for standardization. J Clin Lipidol 2018; 12:264–265.
Holmes MV, Millwood IY, Kartsonaki C, et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J Am Coll Cardiol 2018; 71:620–632.
Sweeney T, Quispe R, Das T, et al. The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review. Expert Rev Precis Med Drug Dev 2021; 6:247–258.
Ala-Korpela M. The culprit is the carrier, not the loads: cholesterol, triglycerides and apolipoprotein B in atherosclerosis and coronary heart disease. Int J Epidemiol 2019; 48:1389–1392.
Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther 2013; 27:559–567.
Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother 2019; 20:127–131.
Stefanutti C. Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Curr Atheroscler Rep 2020; 22:38.
Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid 2019; 14:19–30.
Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2015; 386:452–460.
Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol 2019; 74:1107–1115.
Tun NN, Arunagirinathan G, Munshi SK, Pappachan JM. Diabetes mellitus and stroke: a clinical update. World J Diabetes 2017; 8:235–248.
Choi JY, Kim JS, Kim JH, et al. High free fatty acid level is associated with recurrent stroke in cardioembolic stroke patients. Neurology 2014; 82:1142–1148.
Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329–1339.
Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38:865–873.
Dawson J. Pioglitazone use after stroke: story of hearts, minds, and bones. Circulation 2018; 138:1221–1223.
Lim S, Oh TJ, Dawson J, Sattar N. Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes Obes Metab 2020; 22:6–15.
Spence JD, Viscoli CM, Inzucchi SE, et al. IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS Randomized Clinical Trial. JAMA Neurol 2019; 76:526–535.
Mutie PM, Pomares-Millan H, Atabaki-Pasdar N, et al. An investigation of causal relationships between prediabetes and vascular complications. Nat Commun 2020; 11:4592.
Chang Y, Kim CK, Kim MK, et al. Insulin resistance is associated with poor functional outcome after acute ischemic stroke in nondiabetic patients. Sci Rep 2021; 11:1229.
Ago T, Matsuo R, Hata J, et al. Insulin resistance and clinical outcomes after acute ischemic stroke. Neurology 2018; 90:e1470–e1477.
Fuentes B, Ntaios G, Putaala J, et al. European Stroke Organisation. European Stroke Organisation (ESO) guidelines on glycaemia management in acute stroke. Eur Stroke J 2018; 3:5–21.
Catalina MO, Redondo PC, Granados MP, et al. New insights into adipokines as potential biomarkers for type-2 diabetes mellitus. Curr Med Chem 2019; 26:4119–4144.
Laakso M. Biomarkers for type 2 diabetes. Mol Metab 2019; 27S:S139–S146.
Georgakis MK, Harshfield EL, Malik R, et al. Diabetes mellitus, glycemic traits, and cerebrovascular disease: a Mendelian randomization study. Neurology 2021; 96:e1732–e1742.
Cipolla MJ, Liebeskind DS, Chan SL. The importance of comorbidities in ischemic stroke: impact of hypertension on the cerebral circulation. J Cereb Blood Flow Metab 2018; 38:2129–2149.
O’Donnell MJ, Chin SL, Rangarajan S, et al. INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388:761–775.
Thakkar HV, Pope A, Anpalahan M. Masked hypertension: a systematic review. Heart Lung Circ 2020; 29:102–111.
Hidru TH, Yang X, Xia Y, et al. The relationship between plasma markers and essential hypertension in middle-aged and elderly Chinese population: a community based cross-sectional study. Sci Rep 2019; 9:6813.
Li WY, Jin J, Chen J, et al. Circulating microRNAs as potential noninvasive biomarkers for the early detection of hypertension-related stroke. J Hum Hypertens 2014; 28:288–291.
Amar S, Olanrewaju E, Hemant G. Circulating blood biomarkers in essential hypertension: a literature review. J Lab Precis Med 2017.
Brea D, Sobrino T, Blanco M, et al. Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation. Atherosclerosis 2009; 205:561–567.
Katan M, Moon YP, Paik MC, et al. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study. PLoS One 2014; 9:e83393.
Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: the story continues. Med Res Rev 2020; 40:79–134.
Tian Y, Jia H, Li S, et al. The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with lipoprotein-associated phospholipase A2: a systematic review and meta-analysis. Medicine (Baltimore) 2017; 96:e9413.
Betts MB, Milev S, Hoog M, et al. Comparison of recommendations and use of cardiovascular risk equations by health technology assessment agencies and clinical guidelines. Value Health 2019; 22:210–219.
Danese MD, Pemberton-Ross P, Catterick D, Villa G. Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom. Eur J Prev Cardiol 2020; 2047487319899212.
Montellano FA, Ungethüm K, Ramiro L, et al. Role of blood-based biomarkers in ischemic stroke prognosis: a systematic review. Stroke 2021; 52:543–551.
Yi L, Tang J, Shi C, et al. Pentraxin 3, TNF-α, and LDL-C are associated with carotid artery stenosis in patients with ischemic stroke. Front Neurol 2019; 10:1365.
Georgakis MK, Gill D, Rannikmäe K, et al. Genetically determined levels of circulating cytokines and risk of stroke. Circulation 2019; 139:256–268.
Andone S, Bajko Z, Motataianu A, et al. The role of biomarkers in atherothrombotic stroke-a systematic review. Int J Mol Sci 2021; 22:9032.
Hofmann A, Brunssen C, Wolk S, et al. Soluble LOX-1: a novel biomarker in patients with coronary artery disease, stroke, and acute aortic dissection? J Am Heart Assoc 2020; 9:e013803.
Kurzepa J, Golab P, Czerska S, Bielewicz J. The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke. Int J Neurosci 2014; 124:707–716.
Cui S, Li W, Lv X, et al. Folic acid supplementation delays atherosclerotic lesion development by modulating MCP1 and VEGF DNA methylation levels in vivo and in vitro. Int J Mol Sci 2017; 18:990.
Fonseca AC, Coelho P. Update on biomarkers associated to cardioembolic stroke: a narrative review. Life (Basel) 2021; 11:448.
Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016; 47:895–900.
Freedman B, Kamel H, Van Gelder IC, Schnabel RB. Atrial fibrillation: villain or bystander in vascular brain injury. Eur Heart J Suppl 2020; 22: (Suppl M): M51–M59.
Arnold M, Schütz V, Katan M. Promising biomarker candidates for cardioembolic stroke etiology. a brief narrative review and current opinion. Front Neurol 2021; 12:624930.
Goetze JP, Bruneau BG, Ramos HR, et al. Cardiac natriuretic peptides. Nat Rev Cardiol 2020; 17:698–717.
Katan M, Moon YP, Paik MC, et al. Procalcitonin and midregional proatrial natriuretic peptide as markers of ischemic stroke: the Northern Manhattan Study. Stroke 2016; 47:1714–1719.
De Marchis GM, Schneider J, Weck A, et al. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke. Neurology 2018; 90:e455–e465.
Zhang K, Kamtchum-Tatuene J, Li M, Jickling GC. Cardiac natriuretic peptides for diagnosis of covert atrial fibrillation after acute ischaemic stroke: a meta-analysis of diagnostic accuracy studies. Stroke Vasc Neurol 2021; 6:128–132.
Arnold M, Nakas C, Luft A, et al. Independent prognostic value of MRproANP (Midregional Proatrial Natriuretic Peptide) levels in patients with stroke is unaltered over time. Stroke 2020; 51:1873–1875.
Hosomi N, Yoshimoto T, Kanaya Y, et al. Brain natriuretic peptide and particular left ventricle segment asynergy associated with cardioembolic stroke from old myocardial infarction. J Stroke Cerebrovasc Dis 2016; 25:1165–1171.
Montaner J, Ramiro L, Simats A, et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol 2020; 16:247–264.
Pulit SL, Weng LC, McArdle PF, et al. Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes. Neurol Genet 2018; 4:e293.
Falcione S, Kamtchum-Tatuene J, Sykes G, Jickling GC. RNA expression studies in stroke: what can they tell us about stroke mechanism? Curr Opin Neurol 2020; 33:24–29. This recent review illustrates the role of RNA biomarkers in etiological classification of stroke.
García-Berrocoso T, Palà E, Consegal M, et al. Cardioembolic ischemic stroke gene expression fingerprint in blood: a systematic review and verification analysis. Transl Stroke Res 2020; 11:326–336.
Kim YD, Song D, Nam HS, et al. D-dimer for prediction of long-term outcome in cryptogenic stroke patients with patent foramen ovale. Thromb Haemost 2015; 114:614–622.
Zuin M, Rigatelli G, Rigatelli A, et al. Correlations between serum homocysteine levels and RoPE score in patients with patent foramen ovale. Heart Vessels 2020; 35:705–711.
Sgarra L, Bortone AS, Potenza MA, et al. Endothelial dysfunction may link interatrial septal abnormalities and MTHFR-inherited defects to cryptogenic stroke predisposition. Biomolecules 2020; 10:861.
Wardlaw JM, Smith EE, Biessels GJ, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12:822–838.
Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol 2019; 18:684–696.
Du H, Wilson D, Ambler G, et al. Small vessel disease and ischemic stroke risk during anticoagulation for atrial fibrillation after cerebral ischemia. Stroke 2021; 52:91–99.
Boehme AK, McClure LA, Zhang Y, et al. Inflammatory markers and outcomes after lacunar stroke: levels of inflammatory markers in treatment of stroke study. Stroke 2016; 47:659–667.
Wardlaw JM, Debette S, Jokinen H, et al. ESO Guideline on covert cerebral small vessel disease. Eur Stroke J 2021; 6:CXI–CLXII.
Cannistraro RJ, Badi M, Eidelman BH, et al. CNS small vessel disease: a clinical review. Neurology 2019; 92:1146–1156.
Azizkhanian I, Sheth SA, Iavarone AT, et al. Plasma lipid profiling identifies biomarkers of cerebral microvascular disease. Front Neurol 2019; 10:950.
Moretti R, Giuffré M, Caruso P, et al. Homocysteine in neurology: a possible contributing factor to small vessel disease. Int J Mol Sci 2021; 22:
Rajani RM, Quick S, Ruigrok SR, et al. Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats. Sci Transl Med 2018; 10:2051.
Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke 2015; 10:469–478.